期刊文献+

抑瘤素M联合达卡巴嗪抑制黑色素瘤细胞B16的增殖 被引量:2

Oncostatin M combined with dacarbazine inhibits proliferation of melanoma cell B16
下载PDF
导出
摘要 目的:通过体内外实验探讨抑瘤素M(OSM)联合达卡巴嗪(DTIC)对小鼠黑色素瘤细胞B16的抑制作用。方法:在体外分别采用MTT法和FCM法检测达卡巴嗪单药以及联合OSM对黑色素瘤B16细胞增殖和凋亡的影响;Hochest染色法检测达卡巴嗪单药以及联合OSM对黑色素瘤B16细胞的细胞核形态学变化,研究OSM联合DTIC对黑色素瘤B16细胞的抑制作用;体内实验将黑色素瘤细胞B16接种于小鼠,观察OSM、DTIC及DTIC联合OSM治疗对小鼠的成瘤性的影响。结果:体外实验中OSM、DTIC或DTIC联合OSM对黑色素瘤B16细胞的增殖抑制率分别为11.2±2.3%,25.3±4.6%和32.5±3.8%,差异具有统计学意义(P<0.05),诱导黑色素瘤B16细胞的凋亡率分别为1.32±0.42%,10.64±2.13%和15.86±2.76%,差异具有统计学意义(P<0.05)。在形态学上,DTIC联合OSM可明显引起细胞核破碎增加;在体内实验中,DTIC相对于对照组能明显抑制小鼠黑色素瘤的生长,DTIC联合OSM能增加DTIC的抑瘤作用。结论:OSM联合DTIC体外可以明显抑制黑色素瘤B16细胞增殖,诱导其凋亡,为黑色素瘤的治疗提供了一种新的可能性方案。 Objective:To observe and identify the inhibitory effect of oncostatin M (OSM) combined with dacarbazine (DTIC) on mouse melanoma cells B16 in vitro and in vivo. Methods:The inhibitory effect of OSM combined with DTIC on the proliferation and apoptosis of B16 melanoma cell line B16 were determined through MTT assay and flow cytometry, respectively. The change in nu-cleus morphology of B16 cells was observed under a fluorescence microscope by Hoechst staining method. The effects of single agents OSM and DTIC, as well as OSM-DTIC joint treatments, on tumor in mice in vivo were observed by inoculating B16 cells into C57 BL of six mice. Results:The OSM, DTIC, and combined OSM-DTIC treatments inhibited the proliferation of B16 cells by (11.2±2.3)%, (25.3±4.6)%, and (32.5±3.8)%, respectively (P〈0.05). Apoptosis of B16 occurred at (1.32±0.42)%, (10.64±2.13)%, and (15.86±2.76)%, respectively (P〈0.05). Cell morphology showed a significant increase in nuclear fragmentation, as proven by OSM-DTIC combined treatment. In the in vivo experiment, DTIC caused an apparent inhibition on the growth of mouse melanoma compared with the control group, and the joint treatment showed that the addition of OSM enhanced the tumor suppression effect of DTIC. Conclusion: OSM combined with DTIC has a synergistic effect that inhibits proliferation and apoptosis of B16 in vitro. This approach suggests a new po-tential treatment for melanoma.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第24期1540-1543,共4页 Chinese Journal of Clinical Oncology
关键词 抑瘤素M 达卡巴嗪 黑色素瘤 oncostatin M, DTIC, melanoma
  • 相关文献

参考文献15

  • 1Devries E,Bray FI,Coebergh JW. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997:rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia[J].International Journal of Cancer,2003,(01):119-126.doi:10.1002/ijc.11360. 被引量:1
  • 2Jemal A,Siegel R,Ward E. Cancer statistics,2009[J].CA Can-cer J Clin,2009,(04):225-249. 被引量:1
  • 3Agarwala SS. Current systemic therapy for metastatic melanoma[J].EXPERT REVIEW OF ANTICANCER THERAPY,2009,(05):587-595. 被引量:1
  • 4Avril MF,Aamdal S,Grob JJ. Fotemustine compared with da-carbazine in patients with disseminated malignant melanoma:a phase III study[J].Journal of Clinical Oncology,2004,(06):1118-1125. 被引量:1
  • 5Zarling JM,Shoyab M,Marquardt H. Oncostatin M:a growth regulator produced by differentiated histiocytic lymphoma cells[J].Proceedings of the National Academy of Sciences(USA),1986,(24):9739-9743. 被引量:1
  • 6王亚丽(综述),吴瑾(审校).恶性黑色素瘤诊断与治疗进展[J].中国综合临床,2012,28(11):1226-1228. 被引量:6
  • 7Garbe C,Eigentler TK,Keilholz U. Systematic review of med-ical treatment in melanoma:current status and future prospects[J].Oncologist(the)t,2011,(01):5-24. 被引量:1
  • 8Hervieu A,Rébé C,Végran F. Dacarbazine-mediated upregu-lation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth[J].Journal of Investigative Dermatology,2013,(02):499-508. 被引量:1
  • 9李海夫,林清,孔燕,李丽,代杰,于玮玮,郭军.重组人血管内皮抑制素联合达卡巴嗪增强抗黑素瘤作用及其机制研究[J].肿瘤,2010,30(8):661-665. 被引量:9
  • 10马家芳,孔燕,崔传亮,梁龙,张虔男,唐碧霞,代杰,郭军.MITF基因扩增预测重组人血管内皮抑素联合达卡巴嗪一线治疗晚期黑色素瘤疗效的临床研究[J].临床肿瘤学杂志,2013,18(6):494-497. 被引量:6

二级参考文献58

  • 1Grau C,Overgaard J.Effects of cancer chemotherapy on the hypoxic fraction of solid tumor measured using a local tumor control assay[J].Radiothelr Oncol,1988,13(4):301-309. 被引量:1
  • 2Brown JM.Sensitizers and protectors in radiotherapy[J].Cancer,1985,55(Sup 9):2222-2228. 被引量:1
  • 3Sigounas G,Sallah S.Sigounas VY.Frythropoietin modulates the anticancer activity of chemotherapeutic drugs in a murine lung cancer model[J].Cancer Lett,2004,214(2):171-179. 被引量:1
  • 4L(o)vey J,Bereczky B,Cilly R,et al.Recombinant human erythropoietin alpha improves the efficacy of radiotherapy of a human tumor xenograft,affecting tumor cells and microvessels[J].Strahlenther Onkol,2008,184(1):1-7. 被引量:1
  • 5Silver DF,Piver MS.Effects of recombinant human erythropoietin on the antitumor effect of cisptatin in SCID mice bearing human ovarian cancer:a possible oxygen effect[J].Gynecol Oncol,1999,73(2):280-284. 被引量:1
  • 6Thallinger C,Werzowa J,Poeppl W,et al.Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice[J].J Invest Dermatol,2007,127(10):2411-2417. 被引量:1
  • 7Okazaki T,Ebihara S,Asada M,et al.Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis[J].Neoplasia,2008,10(9):932-939. 被引量:1
  • 8Anagnostou A,Lee KS,Kessimian N,et al.Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells[J].Proc Natl Acad Sci,1990,87(15):5978-5982. 被引量:1
  • 9TSUTSUMID A,FURUKAWA H,YAMAMOTO Y,et al.Treatment strategy for cutaneous malignant melanoma[J].Int J Clin Oncol,2005,10(5):311-317. 被引量:1
  • 10MIDDLETON M,GROB J,AARONSON N,et al.Randomized phase Ⅲ study of temozolomide:dacarbazine in the treatment of patients with advanced metastatic malignant melanoma[J].J Clin Oncol,2000,18(1):158-166. 被引量:1

共引文献19

同被引文献23

  • 1张艳丽,祝顺琴,刘亚玲,崔红娟.恶性黑色素瘤内科治疗研究进展[J].肿瘤防治研究,2014,41(1):74-78. 被引量:13
  • 2陈敬成,兰世杰,袁长吉.晚期黑色素瘤治疗进展[J].中国老年学杂志,2015,35(2):520-523. 被引量:10
  • 3Gogae HJ, Kirkwood JM, Sondak VK. Chemotherapy for meta- static melanoma: time for a change[J]. Cancer,2007,109(3): 455-464. 被引量:1
  • 4Gonzalez-Larriba JL, Berrocal A, Cerezuela P, et al. Retrospective study of the efficacy and safety of fotemustine in 170 patients with metastatic melanoma[C]. J Clin Oncol ASCO Annual Meet- ing Proceedings,2010,28 ( 15 suppl):e 19011. 被引量:1
  • 5Celia D, Huang H, Homesley HD, et al. Patient-reported peripher- al neuropathy of doxorubicin and cisplatin with and without pacli- taxel in the treatment if advanced endometrial cancer: Results from GOG184[J]. Gynecol Oncol,2010,119(3):538-542. 被引量:1
  • 6Daponte A, Ascierto PA, Gravina A, et al. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma: a multicenter phase II study of the Italian Cooperative Oncology Group[J]. Cancer,2000,89(12):2630-2636. 被引量:1
  • 7Atkins MB. Cytokine-based therapy and biochemotherapy for ad- vanced melanoma[J]. Clin Cancer Res,2006,12(7):2353-2358. 被引量:1
  • 8Khayat D, Bernard-Marty C, Meric JB, et al. Biochemotherapy for advanced melanoma: maybe it is real[J]. J Clin Oncol,2002,20 (10):2411-2414. 被引量:1
  • 9Neri B, Vannozzi L, Fulignati C, et al. Long-term survival in meta- static melanoma patients treated with sequential biochemothera- py: report of a phase II study[J]. Cancer Invest,2006,24(5): 474-478. 被引量:1
  • 10脱帅,张宁苏,张宁,杨波.树突细胞联合细胞因子诱导的杀伤细胞对原发性肝脏淋巴瘤生长和术后复发转移的抑制作用[J].解放军医学杂志,2010,35(12):1449-1454. 被引量:6

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部